Statistical Methodology

  1. Guo, B., Huang, L., Yuan, Y. (2023). Treatment Comparisons in Adaptive Platform Trials Adjusting for Temporal Drift. Statistics in Biopharmaceutical Research, In Press.
  2. Guo, B., Laird, G., Song, Y., Chen, J., Yuan, Y. (2023). Adaptive hybrid control design for comparative clinical trials with historical control data. Journal of the Royal Statistical Society, Series C, In Press.
  3. Zang, Y., Guo, B., Qiu, Y., Liu, H., Opyrchal, M., Lu, X. (2023) Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies. Clinical Trials. In Press.
  4. Guo, B., Yuan, Y. (2023). DROID: Dose-ranging Approach to Optimizing Dose in Oncology Drug Development. Biometrics. In Press.
  5. Guo, B., Yuan, Y. (2023). Precision Medicine in Cancer Clinical Trial Designs. Precision Health: Theory, Methods and Applications. Springer Nature. Book chapter.
  6. Lin, L., Han, Y., Zhang, R. Guo, B.  (2023). Biomarker-based precision dose finding for immunotherapy combined with radiotherapy. Biometrical Journal, 65 (7): 2200246. 
  7. Shan, M., Guo, B., Liu, H., Li, Q., Zang, Y. (2023). Bayesian Order Constrained Adaptive (BOCA) Design for Phase II Clinical Trials Evaluating Subgroup-Specific Treatment Effect. Statistical Methods in Medical Research. 32: 885-894.
  8. Guo, B., Zang, Y., Lin, L., Zhang, R. (2023). A Bayesian Phase I/II Design to Determine Subgroup-Specific Optimal Dose for Immunotherapy Sequentially Combined with Radiotherapy. Pharmaceutical Statistics. 22: 143-161.
  9. Guo, B., Yuan, Y. (2022). Complex Innovative Design. Advanced Statistics in Regulatory Critical Clinical Initiatives. Chapman & Hall/CRC Biostatistics Series. Book chapter.
  10. Zhang, Y., Guo, B., Cao, S., Zhang, C., Zang, Y. (2022). SCI: A Bayesian Adaptive Phase I/II Dose-finding Design Accounting for Semi-Competing Risks Outcomes for Immunotherapy Trials. Pharmaceutical Statistics. 21: 960-973.
  11. Guo, B., Zang, Y. (2022). A Bayesian Phase I/II Biomarker-based Design for Identifying Subgroup-Specific Optimal Dose for Immunotherapy. Statistical Methods in Medical Research, 31(6):1104-1119.
  12. Guo, B., Zang, Y. (2022). BIPSE: A Biomarker-based Phase I/II Design for Immunotherapy Trials with Progression-free Survival Endpoint. Statistics in Medicine, 41(7), 1205-1224.
  13. Guo, B., Garrett, L., and Liu, S. (2021). A Bayesian Phase I/II Design for Clinical Trials Combining an Immunotherapeutic Agent with a Chemotherapeutic Agent. Journal of the Royal Statistical Society: Series C, 70(5), 1210-1229.
  14. Guo, B., Zang, Y. (2020). BILITE: A Bayesian Phase II Design for Immunotherapy by Jointly Modeling the Longitudinal Immune Response and Time-to-event Efficacy. Statistics in Medicine, 39(29), 4439-4451.
  15. Guo, B. and Liu, S. (2020). An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints. Biometrical Journal, (62): 339-349.
  16. Zang, Y., Guo, B., Han, Y., Cao, S., Zhang, C. (2019). A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modeling. Statistics in Medicine, (38): 2883-2896.
  17. Guo, B., Park, Y., and Liu, S. (2019). A Utility-based Bayesian phase I/II Design for immunotherapy trials with progression-free survival endpoint. Journal of the Royal Statistical Society: Series C, (68): 411-425.
  18. Guo, B., Zang, Y. (2019). A Bayesian Adaptive Phase II Clinical Trial Design Accounting for Spatial Variation. Statistical Methods in Medical Research, (28): 3187-3204.
  19. Guo, B., Li, D., and Yuan, Y. (2018). SPIRIT: A Seamless Phase I/II Randomized Design for Immunotherapy Trials. Pharmaceutical Statistics, (17): 527-540.
  20. Liu, S., Guo, B., and Yuan, Y. (2018). A Bayesian Phase I/II Trial Design for Immunotherapy. Journal of the American Statistical Association, (113): 1016-1027.
  21. Dale, R., and Guo, B. (2018). Estimating epidemiological parameters of a stochastic differential model of HIV dynamics using hierarchical Bayesian statistics. PLOS ONE. 13(7):e0200126. doi: 10.1371/journal.pone.0200126
  22. Zang, Y. and Guo, B. (2018). Optimal two-stage enrichment design correcting for biomarker misclassification. Statistical Methods in Medical Research, (27): 35-47.
  23. Guo, B. and Liu, S. (2017). Optimal Benchmark for Evaluating Drug-combination Dose-finding Clinical Trials. Statistics in Biosciences, 10(1): 184-201.
  24. Guo, B. and Yuan, Y. (2017). Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents. Journal of the American Statistical Association, (112): 508-520.
  25. Guo, B. and Yuan, Y. (2017). A comparative review of methods for comparing means using partially paired data. Statistical Methods in Medical Research, 26(3): 1323-1340.
  26. Yuan, Y., Guo, B., Munsell, M., Lu, Karen, Jazaeri, A. (2016). MIDAS: a practical Bayesian design for platform trials with immunotherapy agents. Statistics in Medicine, (22): 3892-3906.
  27. Zang, Y. and Guo, B. (2016). Two-stage methods to implement and analyze the biomarker-guided clinical trial designs in the presence of biomarker misclassification. Precision Medicine, 2: e1230. doi: 10.14800/pm.1230.
  28. Guo, B., Zang, Y., and Yuan, Y. (2015). A Bayesian phase I/II clinical trial design in the presence of informative dropouts. Statistics and Its Interface, (8): 217-226.
  29. Guo, B. and Yuan, Y. (2015). A Bayesian dose-finding design for phase I/II clinical trials with non-ignorable dropouts. Statistics in Medicine, (34): 1721-1732.
  30. Guo, B., Li, Y. and Yuan, Y. (2015). A dose-schedule-finding design for phase I/II clinical trials. Journal of the Royal Statistical Society: Series C, (65): 259-272.
  31. Guo, B. and Li, Y. (2015). Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering. Statistics in Medicine, (34): 859-875.
  32. Guo, B. and Li, Y. (2014). Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship. BMC Medical Research Methodology, 14:95.
  33. Guo, B., Villagran, A., Vannucci, M., Wang, J., Davis, C., Man, T., Lau, C. and Guerra, R. (2010). Bayesian estimation of genomic copy number with single nucleotide polymorphism genotyping arrays. BMC Research Notes, 3:350.

Interdisciplinary Research

  1. Chien, C., Zhao, X., Guo, B., Zhang, R. (2023) Technical note: Preprocessing of portal images to improve image quality of VMAT-CT. Medical Physics. In Press
  2. Zhang, R., Clark, S., Guo, B., Zhang, T., Jeansonne, D., Jeyaseelan, S., Francis, J., Huang, W. (2023) Challenges in the combination of radiotherapy and immunotherapy for breast cancer. Expert Review of Anticancer Therapy. 4: 375-383.
  3. Zhang, R., *Xie, Y., *DiTusa, C., *Ohler R., *Heins, D., Bourgeois D., Guo, B. (2022) Flattening-filter-free volumetric modulated arc radiotherapy for left-sided whole breast, partial breast, and post-mastectomy irradiations. Journal of Medical Physics, 47(2):166-172.
  4. Zhang, Z., Sun, C., Guo, B., (2022). Transfer-Learning Guided Bayesian Model Updating for Damage Identification Considering Modeling Uncertainty. Mechanical Systems and Signal Processing. 166(3): 108426.
  5. Xie, Y., Guo, B., Zhang, R. (2021). Cost-Effectiveness Analysis of Radiotherapy Techniques for Whole Breast Irradiation. PLOS ONE. In press.
  6. Xie, Y., Guo, B., Zhang, R. (2020). Cost-effectiveness analysis of advanced radiotherapy techniques for post-mastectomy breast cancer patients. Cost Effectiveness and Resource Allocation. In Press
  7. Xie, Y., Bourgeois, D., Guo, B., Zhang, R. (2020). Comparison of conventional and advanced radiotherapy techniques for left-sided breast cancer after breast conserving surgery. Medical Dosimetry. In Press.
  8. Pandey, A., Yoganathan, A., Guo, B., Zhang, R. (2019). Feasibility of generating synthetic CT from T1-weighted MRI using a linear mixed-effects regression model. Biomedical Physics & Engineering Express. In Press.
  9. Xie, Y., Bourgeois, D., Guo, B., Zhang, R. (2019). Post-mastectomy radiotherapy for left-sided breast cancer patients: comparison of advanced techniques. Medical Dosimetry. In Press.
  10. Bakhit, P., Osman, O., Guo, B., Ishak, S. (2018).  A Distraction Index for Quantification of Driver Eye Glance Behavior: A Study Using SHRP2 NEST Database. Journal of Safety Science.
  11. Zhang, R., Heins, D., Sanders, M., Guo, B., Hogstrom, K. (2018). Evaluation of a mixed beam therapy for post-mastectomy breast cancer patients: bolus electron conformal therapy combined with intensity modulated photon radiotherapy and volumetric modulated photon arc therapy. Medical Physics. DOI: 10.1002/mp.12958.
  12. Bakhit, P., Guo, B., Ishak, S. (2018). Crash and Near-Crash Risk Assessment of Distracted Driving and Engagement in Secondary Tasks: A Naturalistic Driving Study. Journal of the Transportation Research Board. DOI: 10.1177/0361198118772703.
  13. Heppner, W., Spears, C., Fernandez, V., Castro, Y., Li, Y., Guo, B., Reitzel, L., Vidrine, J., Mazas, C., Woerpel, L., Cinciripini, P., Ahluwalia, J., Wetter, D. (2016). Dispositional Mindfulness Predicts Enhanced Smoking Cessation and Smoking Lapse Recovery. Annals of Behavioral Medicine. (50) 337-347.
  14. Xu, W., Chafi, H., Guo, B., Heymsfield, S., Murray, K. Zheng, J., Jia, G. (2016). Quantitative Comparison of Two Dual-Energy X-ray Absorptiometry (DXA) Systems in Assessing Body Composition and Bone Mineral Measurements. Journal of Clinical Densitometry. 19(3) 298-304.
  15. Chafi, H., Elias, S., Nguyen, H., Friel, H., Knopp, M., Guo, B., Heymsfield, S., Jia, G. (2015). Effect of parallel radiofrequency transmission on arterial input function selection in dynamic contrast-enhanced 3 Tesla Pelvic MRI. Journal of Magnetic Resonance Imaging, (43) 229-235.
  16. Shah, Z., Elias, S., Abaza, R., Zynger, D., DeRenne, L., Knopp, M., Guo, B., Schurr, R., Heymsfield, S., Jia, G. (2015). Performance Comparison of 1.5-T Endorectal Coil MRI with 3.0-T Nonendorectal Coil MRI in Patients with Prostate Cancer. Academic Radiology, 22(4) 467-474.
  17. Zang, Y. and Guo, B. (2016) Enrichment design accommodating the biomarker misclassification. Atlas of Science, March 13, 2016.
  18. Guo, B. and Zhang, R. (2018). Statistical Methods for Clinical Trial Designs in the New Era of Cancer Treatment. Biostatistics and Biometrics Open Access Journal, 5(3).